Supernus Pharmaceuticals | SUPN - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Abbott USD 42M 2M 2025-12
ANI Pharmaceuticals USD 4.41M 316K 2025-12
Aurora Cannabis CAD 2.11M 116K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Canopy Growth CAD 7.34M 1.46M 2025-12
Cara Therapeutics 43.75M 4.8M 2025-06
Corcept Therapeutics USD 823.61M 21.88M 2025-09
Eisai JPY 1.43B 12M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Novo Nordisk DKK 1.53B 3.43B 2025-09
Pacira USD 3.89M 387K 2025-12
Perrigo USD 10.08B 10.04B 2025-09
Pfizer USD 711M 59M 2025-12
Supernus Pharmaceuticals USD 910K 278K 2023-06
United Therapeutics USD 3.1M 100K 2025-12
Xeris Pharmaceuticals USD 7.15M 115K 2025-12